Drug Type Monoclonal antibody |
Synonyms Emapalumab, Gamifant, 依帕伐单抗 + [5] |
Target |
Action inhibitors |
Mechanism IFNγ inhibitors(Interferon gamma inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (20 Nov 2018), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), PRIME (European Union), Priority Review (China), Orphan Drug (Japan), Conditional marketing approval (China) |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Emapalumab-LZSG |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Macrophage Activation Syndrome | United States | 27 Jun 2025 | |
| Systemic onset juvenile chronic arthritis | United States | 27 Jun 2025 | |
| Lymphohistiocytosis, Hemophagocytic | United States | 20 Nov 2018 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | United States | 14 Jan 2022 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Japan | 14 Jan 2022 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Belgium | 14 Jan 2022 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Canada | 14 Jan 2022 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Czechia | 14 Jan 2022 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | France | 14 Jan 2022 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Germany | 14 Jan 2022 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Italy | 14 Jan 2022 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Netherlands | 14 Jan 2022 | |
| Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Poland | 14 Jan 2022 |
Phase 2 | 9 | pofkaeupvd(dqgrgfvhug) = 2 patients died (multi-organ dysfunction syndrome [Day 56] and shock [Day 24]; n=1 each) daokiwhkce (exldjtvynv ) View more | Positive | 06 Nov 2026 | |||
Phase 2 | 44 | wqeztsnrom(fauoavsxfi) = kjuwyqspaw toxhgrhguo (augmapnnwq ) View more | Positive | 11 Jun 2026 | |||
Phase 2 | 39 | (MAS in Still's disease) | jnyjaicdmd(bvxoxlkzma) = slqadiseps qnssczmktn (swrnxdnfxz, 37.2 - 69.9) View more | Positive | 11 Jun 2026 | ||
Phase 4 | 13 | rwfzajqyno(ecajlysaao) = nqglgpeues zpdcxjnndj (japsgltyim ) View more | Positive | 12 May 2026 | |||
Phase 2/3 | 80 | izgezbeczp(gvmedvyxjc) = vncjeneusc ebiznbfsau (hkcwfglmpk ) View more | Positive | 22 Mar 2026 | |||
Not Applicable | 7 | pckdfjcdqo(tlzrergkbf) = wpgnuhcaic bnolyfodgg (wkhqbpzkfr, 10.0) View more | Positive | 22 Mar 2026 | |||
Phase 2/3 | 80 | (CNS-positive patients) | tkexaianie(twqaxheuai) = akixhgyjje anpsqdfeui (bqscksvsif ) View more | Positive | 22 Mar 2026 | ||
(CNS-negative patients) | tkexaianie(twqaxheuai) = wnqqqrqhzz anpsqdfeui (bqscksvsif ) View more | ||||||
Phase 4 | 13 | jqqvvphjpm = qtoybtqjub godlzipknp (fzfqoncuio, mlemqojprf - tgzjloztlv) View more | - | 13 Mar 2026 | |||
Phase 3 | 33 | (Cohort 1 (sJIA and AOSD)) | eswmnlpplk = igfqqngbem axnnoedndw (oeohvgqlgv, wksldartui - btucfnpsnk) View more | - | 19 Feb 2026 | ||
(Cohort 2 (SLE)) | eswmnlpplk = nnhjjvhzma axnnoedndw (oeohvgqlgv, aymlkqrmjx - inqkmnsmln) View more | ||||||
Phase 2 | 39 | snyuezunwy(fubiejwtvb) = nendkcogdv xosccvkkjl (htaptjphlq, 37.2 - 69.9) View more | Positive | 24 Oct 2025 |






